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INTRODUCTION
 
  
Dicloxacillin(DCX) is chemically 9(2S,5R,6R)-6-[3-(2,6-
dichlorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-
dimethyl-7-oxo-4-thia-1 azabicyclo [3.2.0] heptane-2-
carboxylic acid 
1
, is a penicillinase resistant penicillin, 
used in the treatment of bacterial infections such as 
pneumonia and bone, ear, skin and urinary tract infection 
2
. 
It is official in IP and USP. IP 
3
 and USP 
4
 describe RP-
HPLC method for its estimation. Literature survey reveals 
HPLC 
5
 method for determination of DCX in 
pharmaceutical dosage forms as well as in biological 
fluids. Literature survey also reveals spectofluorimetric 
6 
and RP-HPLC 
7-9
 methods for determination of DCX with 
other drugs. Cefpodoxime proxetil (CEF) is chemically 1-
(isopropoxy carbonyloxy) ethyl (6R,7R)-7-[2-(2-amino-4-
thiazolyl)-(z)-2-(methoxyimino) acetamido]-3-
methoxymethyl-3-cephem-4-carboxylate 
10
, is a third 
generation cephalosporin antibiotic. It is used for 
infections of the respiratory tract, urinary tract and skin 
and soft tissues. It has greater activity against 
staphylococcus aureus 
11
. Cefpodoxime proxetil is official 
in IP and USP. IP 
12
 and USP 
13
 describe liquid 
chromatography method for its estimation. Literature 
survey reveals HPTLC 
14
 method for the determination of 
CEF. Literature survey also reveals RP-HPLC 
15
 and 
spectofluorimetric 
16
 methods for determination of CEF 
with other drugs. The combined dosage forms of DCX and 
CEF are available in the market for the treatment of 
infections caused by susceptible micro-organisms Vis. 
Urinary tract infections and gonococcal urethritis. The 
combination of these two drugs is not official in any 
pharmacopoeia, hence no official method is available for 
the simultaneous estimation of DCX and CEF in their  
 
combined dosage forms. Literature survey does not reveal 
any simple spectrophotometric or other method for 
simultaneous estimation of DCX and CEF in combined 
dosage forms. The present communication describes 
simple, sensitive, rapid, accurate and economical 
spectrophotometric method based on dual wavelength 
spectrophotometric method for simultaneous estimation of 
both drugs in their combined tablet dosage forms. 
MATERIALS AND METHODS 
Apparatus 
A shimadzu model 1700 (Japan) double beam UV/Visible 
spectrophotometer with spectral width of 2 nm, 
wavelength accuracy of 0.5 nm and a pair of 10 mm 
matched quartz cell was used to measure absorbance of all 
the solutions. Spectra were automatically obtained by UV-
Probe system software. A Sartorius CP224S analytical 
balance (Gottingen, Germany), an ultrasonic bath 
(Frontline FS 4, Mumbai, India) was used in the study.  
Reagents and Materials 
DCX and CEF bulk powder was kindly gifted by Acme 
Pharmaceuticals Ltd. Ahmedabad, India. The commercial 
fixed dose combination product was procured from the 
local market. Methanol AR Grade was procured from S. D. 
Fine Chemicals Ltd., Mumbai, India. 
Preparation of standard stock solutions 
An accurately weighed quantity of DCX (10 mg) and CEF 
(10 mg) were transferred to a separate 100 ml volumetric 
flask and dissolved and diluted to the mark with methanol 
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to obtain standard solution having concentration of DCX 
(100 μg/ml) and CEF (100 μg/ml).  
Methodology 
The standard solutions of DCX (10 µg/ml) and CEF (10 
µg/ml) were scanned separately in the UV range of 200-
400 nm. The zero-order spectra thus obtained was then 
processed to obtain first-derivative spectra. Data were 
recorded at an interval of 1 nm. The two spectra were 
overlain and it appeared that DCX showed zero crossing at 
321 nm, while CEF showed zero crossing at 233.8 nm. At 
the zero crossing point (ZCP) of DCX (321 nm), CEF 
showed a first-derivative absorbance, whereas at the ZCP 
of CEF (233.8 nm), DCX showed a first-derivative 
absorbance. Hence 233.8 and 321 nm was selected as 
analytical wavelengths for determination of DCX and 
CEF, respectively. These two wavelengths can be 
employed for the determination of DCX and CEF without 
any interference from the other drug in their combined 
dosage formulations. 
17 
 
Figure 1: Overlain zero-order absorption spectra of DCX and CEF in methanol 
 
Figure 2: Overlain first-order derivative spectra of DCX and CEF in methanol 
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Validation of the proposed method 
The proposed method was validated according to the 
International Conference on Harmonization (ICH) 
guidelines. 
[18]
 
Linearity (Calibration curve) 
The calibration curves were plotted over a concentration 
range of 10-80 μg/ml for DCX and 4-32 μg/ml for CEF. 
Accurately measured standard solutions of DCX (1.0, 2.0, 
3.0, 4.0, 5.0, 6.0, 7.0 and 8.0 ml) and CEF (0.4, 0.8, 1.2, 
1.6, 2.0, 2.4, 2.8 and 3.2 ml) were transferred to a series of 
10 ml of volumetric flasks and diluted to the mark with 
methanol. First-derivative absorbance (D1) was measured 
at 233.8 nm for DCX and 321 nm for CEF. The calibration 
curves were constructed by plotting absorbances versus 
concentrations and the regression equations were 
calculated.
 18
       
Method precision (repeatability) 
The precision of the instrument was checked by repeated 
scanning and measurement of absorbance of solution (n = 
6) for DCX and CEF (10 µg/ml) without changing the 
parameter of the first-derivative spectrophotometry 
method.
 18
       
Intermediate precision (reproducibility) 
The intraday and interday precision of the proposed 
method was determined by analyzing the corresponding 
responses 3 times on the same day and on 3 different days 
over a period of 1 week for 3 different concentrations of 
standard solutions of DCX and CEF (20, 50, 80 µg/ml for 
DCX and 8, 20, 32 µg/ml for CEF). The result was 
reported in terms of relative standard deviation (% RSD).
 
18
       
Accuracy (recovery study) 
The accuracy of the method was determined by calculating 
recovery of DCX and CEF by the standard addition 
method. Known amounts of standard solutions of DCX 
and CEF were added at 50, 100 and 150 % level to 
prequantified sample solutions of DCX and CEF (30 µg/ml 
for DCX and 6 µg/ml for CEF). The amounts of DCX and 
CEF were estimated by applying obtained values to the 
respective regression line equations. The experiment was 
repeated for five times.
 18
 
Table 1: Recovery data of proposed method 
Drug Level Amount taken 
(µg/ml) 
Amount added (µg/ml) % Mean recovery ± S.D. (n = 
6) 
 
DCX 
 
I 30 15 101.15 ± 0.08 
II 30 30 102.04± 0.14 
III 30 45 98.93 ± 0.93 
 
CEF 
I 6 3 99.42 ± 0.91 
II 6 6 99.71 ± 1.79 
III 6 9 99.98 ± 1.45 
S. D. is Standard deviation and n is number of determinations 
Limit of detection and Limit of quantification  
The limit of detection (LOD) and the limit of 
quantification (LOQ) of the drug were derived by 
calculating the signal-to-noise ratio (S/N, i.e., 3.3 for LOD 
and 10 for LOQ) using the following equations designated 
by International Conference on Harmonization (ICH) 
guidelines.
18
 
LOD = 3.3 × σ/S 
LOQ = 10 × σ/S 
Where, σ = the standard deviation of the response and S = 
slope of the calibration curve.   
Analysis of DCX and CEF in combined tablet dosage 
form  
Twenty Tablets were weighed and powdered. The powder 
equivalent to 50 mg of DCX and 10 mg of CEF was 
transferred to a 100 ml volumetric flask. Methanol (50 ml) 
was added to it and sonicated for 20 min. The solution was 
filtered through Whatman filter paper No. 41 and the 
volume was adjusted up to the mark with methanol. This 
solution is expected to contain 100 µg/ml of DCX and 100 
µg/ml of CEF. This solution (1.0 ml) was taken in to a 10 
ml volumetric flask and the volume was adjusted up to 
mark with methanol to get a final concentration of DCX 
(50 µg/ml) and CEF (10 µg/ml). The responses of the 
sample solution were measured at 233.8 nm and 321 nm 
for quantification of DCX and CEF, respectively. The 
amounts of the DCX and CEF present in the sample 
solution were calculated by fitting the responses into the 
regression equation for DCX and CEF in the proposed 
method. 
18 
 
Table 2: Analysis of CEF and DCX by proposed method 
Tablet 
 
Label claim (mg) Amount found (mg) % Label claim ± S.D. (n=6) 
CEF  DCX  CEF  DCX) CEF  DCX  
I 100 500 100.8 499 100.80 99.80 
II 100 500 101.4 498.6 101.40 99.72 
S. D. is Standard deviation and n is number of determinations 
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Table 3: Regression analysis data and summary of validation parameters for the proposed method 
PARAMETERS First-derivative UV Spectrophotometry 
DCX at 233.8 nm CEF at 321 nm 
Concentration range (µg/ml) 10-80 4-32 
Regression equation (y = a + bc) 
Slope (b) 
Intercept (a) 
y = 0.00102x - 0.00069    
0.00102 
-0.00069 
y = 0.00029x + 0.00019  
0.00029 
0.00019 
Correlation Coefficient (r
2
) 0.9993 0.9990 
Sandell’s sensitivity (µg/cm2/0.001 A.U.) 0.0333 0.0254 
Accuracy (% recovery),    (n = 6) 100.70 ± 0.38 99.90 ± 0.36 
Repeatability (%RSD
a
, n = 6),  0.058 0.282 
Interday (n = 3) (%RSD)  0.576-0.793 % 0.694-1.005 % 
Intraday(n = 3) (%RSD)  0.212-0.565 % 0.344-0.827 % 
LOD
b 
(µg/ml) 0.56 μg/ml 0.64 μg/ml 
LOQ
c
 (µg/ml) 1.70 μg/ml 1.93 μg/ml 
aRSD = Relative standard deviation. bLOD = Limit of detection. cLOQ = Limit of quantification 
RESULTS AND DISCUSSION 
The standard solutions of DCX and CEF were scanned 
separately in the UV range, and zero-order spectra (Figure 
1) thus obtained was then processed to obtain first-
derivative spectra. Data were recorded at an interval of 1 
nm. The two derivative spectra showed maximum 
absorbance at 233.8 nm (ZCP of CEF) for DCX and 321 
nm (ZCP of DCX) for CEF. First-derivative absorbances 
(D1) were recorded 233.8 nm for DCX and 321 nm for 
CEF (Figure 2). First derivative spectra give good 
quantitative determination of both the drugs at their 
respective without any interference from the other drug in 
their combined dosage formulations. Second and third-
ordered derivative spectra of the drugs were not tested 
because the first-order spectra give satisfactory ZCPs and 
good quantitative determination of both the drugs without 
any interference. 
Linear correlation was obtained between absorbances and 
concentrations of DCX and CEF in the concentration 
ranges of 10-80 µg/ml and 4-32 µg/ml, respectively. The 
linearity of the calibration curve was validated by the high 
values of correlation coefficient of regression (Table 3). 
The RSD values for DCX and CEF were found to be 0.058 
and 0.282 %, respectively (Table 3). The low values of 
relative standard deviation (less than 2 %) indicate that the 
proposed method is repeatable. The low RSD values of 
interday (0.576-0.793 and 0.694-1.005 %) and intraday 
(0.212-0.565 and 0.344-0.827 %) for DCX and CEF, 
respectively, reveal that the proposed method is precise 
(Table 3). LOD values for DCX and CEF were found to be 
0.56 and 0.64 µg/ml, respectively and LOQ values for 
DCX and CEF were found to be 1.70 and 1.93 µg/ml, 
respectively (Table 3). These data show that proposed 
method is sensitive for the determination of DCX and 
CEF. 
The recovery experiment was performed by the standard 
addition method. The mean recoveries were 100.70 ± 0.38 
and 99.90 ± 0.36 % for DCX and CEF, respectively (Table 
1). The results of recovery studies indicate that the 
proposed method is accurate. The proposed validated 
method was successfully applied to determine DCX and 
CEF in their combined dosage form. The results obtained 
for DCX and CEF were comparable with the 
corresponding labeled amounts (Table 3). No interference 
of the excipients with the absorbance of interest appeared, 
hence the proposed method is applicable for the routine 
simultaneous estimation of DCX and CEF in 
pharmaceutical dosage forms.  
CONCLUSION 
Based on the results, obtained from the analysis of 
described method, it can be concluded that the method has 
linear response in the range of 10-80 μg/ml and 4-32 μg/ml 
for DCX and CEF, respectively with co-efficient of 
correlation, (r
2
)=0.9993 and (r
2
) = 0.9990 for DCX and 
CEF, respectively. The result of the analysis of 
pharmaceutical formulation by the proposed method is 
highly reproducible and reliable and it is in good 
agreement with the label claim of the drug. The additives 
usually present in the pharmaceutical formulation of the 
assayed sample did not interfere with determination of 
DCX and CEF. The method can be used for the routine 
analysis of the DCX and CEF in combined dosage form 
without any interference of excipients. 
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